• In mid-June 2026, Leidos Holdings’ outlook was shaken as major analysts downgraded the stock and the Defense Health Agency moved to replace Leidos as lead systems integrator for the Military Health System’s electronic health record program.
• This combination of analyst skepticism and potential reshaping of a flagship federal health IT role has sharpened investor focus on Leidos’ contract mix and segment resilience.
• We’ll examine how the Defense Health Agency’s plan to reduce reliance on Leidos as lead integrator reshapes the company’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Leidos Holdings Investment Narrative Recap

To own Leidos today, you need to believe its mix of defense technology, intelligence, and health contracts can support steady earnings despite policy and budgeting swings. The biggest near term catalyst is how the market reassesses the stock after the Defense Health Agency signaled it will reduce reliance on Leidos as lead systems integrator for Military Health System electronic records. The biggest risk is that this shift exposes broader vulnerability in the health segment’s margins and contract structure.

Against that health cloud, Leidos’ June rollout of the cloud based Joint Management Tool with the Defense Information Systems Agency and U.S. Space Command underscores its role in modern, software heavy military communications. This program, which consolidates satellite communications oversight and sharply cuts reporting time, points back to one of the key positive catalysts: demand for digital modernization and AI enabled mission software that can support higher quality, potentially better margin defense work.

Yet beneath this stronger defense tech story, investors should also be aware that...

Leidos Holdings' narrative projects $20.4 billion revenue and $1.7 billion earnings by 2029.

Uncover how Leidos Holdings' forecasts yield a $183.27 fair value, a 71% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Leidos could reach about US$21.5 billion in revenue and US$1.8 billion in earnings by 2029, far above consensus. Their view leans heavily on continued growth in managed health contracts and Veterans exams, so the Defense Health Agency’s move introduces a direct challenge to that thesis and is a good reminder that even well argued narratives can shift quickly as contract structures change.

Explore 2 other fair value estimates on Leidos Holdings - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Leidos Holdings research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Leidos Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Leidos Holdings' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.